Primary Sclerosing Cholangitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The Primary Sclerosing Cholangitis pipeline market research report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects.
What are the key targets in the Primary Sclerosing Cholangitis pipeline market?
The key targets in the Primary Sclerosing Cholangitis pipeline market are Ileal Sodium/Bile Acid Cotransporter, Integrin Beta 6, Integrin Alpha V, Integrin Beta 1, Prostaglandin G/H Synthase 2, Transforming Growth Factor Beta 1, Bile Acid Receptor, Bile Salt Export Pump, Integrin Alpha 5, and C-C Motif Chemokine 24. Ileal Sodium/Bile Acid Cotransporter has the highest number of pipeline products in the Primary Sclerosing Cholangitis pipeline market.
For more target insights, download a free report sample
What are the key MoA in the Primary Sclerosing Cholangitis pipeline market?
The key MoA in the Primary Sclerosing Cholangitis pipeline market are Ileal Sodium/Bile Acid Cotransporter Inhibitor, Integrin Beta 6 Antagonist, Integrin Alpha V Antagonist, Integrin Beta 1 Antagonist, Prostaglandin G/H Synthase 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Bile Acid Receptor Agonist, Bile Salt Export Pump Inhibitor, Integrin Alpha 5 Antagonist, and C-C Motif Chemokine 24 Inhibitor. Ileal Sodium/Bile Acid Cotransporter Inhibitor has the highest number of pipeline products in the Primary Sclerosing Cholangitis pipeline market.
Primary Sclerosing Cholangitis pipeline market, by MoA
For more MoA insights, download a free report sample
What are the key RoA in the Primary Sclerosing Cholangitis pipeline market?
The key RoA in the Primary Sclerosing Cholangitis pipeline market are oral, intravenous, subcutaneous, inhalational, intradermal, intratumor, and topical. Oral has the highest number of pipeline product in the Primary Sclerosing Cholangitis pipeline market.
Primary Sclerosing Cholangitis pipeline market, by RoA
For more RoA insights, download a free report sample
What are the key molecule type in the Primary Sclerosing Cholangitis pipeline market?
The key molecule type in the Primary Sclerosing Cholangitis pipeline market are Small Molecule, Antisense RNAi Oligonucleotide, Biologic, Recombinant Protein, Cell Therapy, Monoclonal Antibody, Peptide, Subunit Vaccine, and Synthetic Peptide. Small Molecule has the highest number of pipeline products in the Primary Sclerosing Cholangitis pipeline market.
Primary Sclerosing Cholangitis pipeline market, by molecule type
For more molecule type insights, download a free report sample
Which are the key companies in the Primary Sclerosing Cholangitis pipeline market?
The key companies in the Primary Sclerosing Cholangitis pipeline market are Pliant Therapeutics Inc, Sirnaomics Inc, Albireo Pharma Inc, HighTide Therapeutics Inc, Mirum Pharmaceuticals Inc, Qing Bile Therapeutics Inc, AbbVie Inc, Avolynt Inc, BiomX Inc, Cadila Healthcare Ltd, Cascade Pharmaceuticals Inc, and Chemomab Therapeutics Ltd.
Primary Sclerosing Cholangitis pipeline market, by companies
To know more about key companies, download a free report sample
Market report overview
| Key target | Ileal Sodium/Bile Acid Cotransporter, Integrin Beta 6, Integrin Alpha V, Integrin Beta 1, Prostaglandin G/H Synthase 2, Transforming Growth Factor Beta 1, Bile Acid Receptor, Bile Salt Export Pump, Integrin Alpha 5, and C-C Motif Chemokine 24 |
| Key MoA | Ileal Sodium/Bile Acid Cotransporter Inhibitor, Integrin Beta 6 Antagonist, Integrin Alpha V Antagonist, Integrin Beta 1 Antagonist, Prostaglandin G/H Synthase 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Bile Acid Receptor Agonist, Bile Salt Export Pump Inhibitor, Integrin Alpha 5 Antagonist, and C-C Motif Chemokine 24 Inhibitor |
| Key RoA | Oral, Intravenous, Subcutaneous, Inhalational, Intradermal, Intratumor, and Topical |
| Key molecule type | Small Molecule, Antisense RNAi Oligonucleotide, Biologic, Recombinant Protein, Cell Therapy, Monoclonal Antibody, Peptide, Subunit Vaccine, and Synthetic Peptide |
| Key companies | Pliant Therapeutics Inc, Sirnaomics Inc, Albireo Pharma Inc, HighTide Therapeutics Inc, Mirum Pharmaceuticals Inc, Qing Bile Therapeutics Inc, AbbVie Inc, Avolynt Inc, BiomX Inc, Cadila Healthcare Ltd, Cascade Pharmaceuticals Inc, and Chemomab Therapeutics Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Albireo Pharma Inc
Avolynt Inc
BiomX Inc
Cadila Healthcare Ltd
Cascade Pharmaceuticals Inc
Chemomab Therapeutics Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Emergent Biotechnologies LLC
Engitix Ltd
Escient Pharmaceuticals Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Iltoo Pharma
Immunic Inc
Intercept Pharmaceuticals Inc
LISCure Biosciences Co Ltd
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Orbsen Therapeutics Ltd
Parvus Therapeutics Inc
Pliant Therapeutics Inc
Qing Bile Therapeutics Inc
Scohia Pharma Inc
Sirnaomics Inc
Takeda Pharmaceutical Co Ltd
Yungjin Pharm Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Primary Sclerosing Cholangitis pipeline market?
The key targets in the Primary Sclerosing Cholangitis pipeline market are Ileal Sodium/Bile Acid Cotransporter, Integrin Beta 6, Integrin Alpha V, Integrin Beta 1, Prostaglandin G/H Synthase 2, Transforming Growth Factor Beta 1, Bile Acid Receptor, Bile Salt Export Pump, Integrin Alpha 5, and C-C Motif Chemokine 24.
-
What are the key MoA in the Primary Sclerosing Cholangitis pipeline market?
The key MoA in the Primary Sclerosing Cholangitis pipeline market are Ileal Sodium/Bile Acid Cotransporter Inhibitor, Integrin Beta 6 Antagonist, Integrin Alpha V Antagonist, Integrin Beta 1 Antagonist, Prostaglandin G/H Synthase 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Bile Acid Receptor Agonist, Bile Salt Export Pump Inhibitor, Integrin Alpha 5 Antagonist, and C-C Motif Chemokine 24 Inhibitor. Ileal Sodium/Bile Acid Cotransporter Inhibitor has the highest number of pipeline products in the Primary Sclerosing Cholangitis pipeline market.
-
What are the key RoA in the Primary Sclerosing Cholangitis pipeline market?
The key RoA in the Primary Sclerosing Cholangitis pipeline market are oral, intravenous, subcutaneous, inhalational, intradermal, intratumor, and topical.
-
What are the key molecule type in the Primary Sclerosing Cholangitis pipeline market?
The key molecule type in the Primary Sclerosing Cholangitis pipeline market are Small Molecule, Antisense RNAi Oligonucleotide, Biologic, Recombinant Protein, Cell Therapy, Monoclonal Antibody, Peptide, Subunit Vaccine, and Synthetic Peptide.
-
Which are the key companies in the Primary Sclerosing Cholangitis pipeline market?
The key companies in the Primary Sclerosing Cholangitis pipeline market are Pliant Therapeutics Inc, Sirnaomics Inc, Albireo Pharma Inc, HighTide Therapeutics Inc, Mirum Pharmaceuticals Inc, Qing Bile Therapeutics Inc, AbbVie Inc, Avolynt Inc, BiomX Inc, Cadila Healthcare Ltd, Cascade Pharmaceuticals Inc, and Chemomab Therapeutics Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports